A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
• Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
• Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction
• Leukocytes \>= 3,000/uL
• Absolute neutrophil count \>= 1,500/uL
• Platelets \>= 60,000/Ul
• Serum creatinine =\< 1.5 mg/dL
• Distant metastatic disease of peritoneum:
‣ Positive peritoneal cytology
⁃ Carcinomatosis on diagnostic laparoscopy or laparotomy
⁃ Completion of preoperative systemic chemotherapy